$30 Million Settlement Approved in Restasis Antitrust Litigation

A federal judge in the Eastern District of New York has preliminarily approved a settlement of an antitrust class action against Allergan concerning the price of Restasis, a prescription drug used to treat dry-eye problems.

Allergan will pay approximately $30 million to settle all claims in the lawsuit brought on behalf of a certified class of consumers and other end-payors.

If you bought or provided reimbursement for Restasis between May 1, 2015 and July 31, 2021, you may be eligible for a payment. For instructions on how to file your claim, visit https://www.restasislitigation.com/.

Click here to read more about Girard Sharp’s track record of successfully helping clients achieve precedent-setting outcomes against some of the nation’s biggest pharmaceutical companies.

Practice Areas